Live Breaking News & Updates on European medical oncology

Stay informed with the latest breaking news from European medical oncology on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in European medical oncology and stay connected to the pulse of your community

Prehabilitation to improve lung cancer outcomes 1: principles and benefits

Prehabilitation to improve lung cancer outcomes 1: principles and benefits
nursingtimes.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nursingtimes.net Daily Mail and Mail on Sunday newspapers.

United-kingdom , London , City-of , Rotherham , Greater-manchester , United-kingdom-general- , United-states , American , British , Jackie-fenemore , Van-rooijen , Translational-lung-cancer-research

Onxeo receives Notice of Allowance for a AsiDNA patent

Onxeo receives Notice of Allowance for a AsiDNA patent
selectscience.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from selectscience.net Daily Mail and Mail on Sunday newspapers.

United-states , Judith-greciet , Trademark-office , Product-news , Notice-allowance , Chief-executive-officer , Englj-med , European-medical-oncology , ஒன்றுபட்டது-மாநிலங்களில் , முத்திரை-அலுவலகம் , ப்ராடக்ட்-செய்தி , தலைமை-நிர்வாகி-அதிகாரி

Onxeo Receives Notice of Allowance for a New Patent

Onxeo S.A.
Onxeo” or “
the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that it has received from the U.S. Patent and Trademark Office (USPTO), a Notice Allowance for a patent which enhances in the United States the protection of AsiDNA™, its first-in-class inhibitor of tumor DNA repair, in combination with any PARP inhibitor (PARPi). This patent protects both the combination of AsiDNA™ with a PARPi and its use for the treatment of certain cancers for which the DNA repair pathway via homologous recombination (HR) is not impaired or deficient. These so-called HR-proficient tumors are significantly less sensitive to treatment with PARP inhibitors.

United-states , Paris , France-general , France , Copenhagen , Køavn , Denmark , Nicolas-merigeau , Onxeo-sa-euronext , Valerie-leroy , Judith-greciet , Emmanuel-huynh

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA in Combination With a PARP Inhibitor in the United States

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA in Combination With a PARP Inhibitor in the United States
Regulatory News:
Onxeo" or "
the Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that it has received from the U.S. Patent and Trademark Office (USPTO), a Notice Allowance for a patent which enhances in the United States the protection of AsiDNA, its first- in-class inhibitor of tumor DNA repair, in combination with any PARP inhibitor (PARPi). This patent protects both the combination of AsiDNA with a PARPi and its use for the treatment of certain cancers for which the DNA repair pathway via homologous recombination (HR) is not impaired or deficient. These so-called HR-proficient tumors are significantly less sensitive to treatment with PARP inhibitors.

United-states , Paris , France-general , France , Copenhagen , Køavn , Denmark , Nicolas-merigeau , Onxeo-sa-euronext , Valerie-leroy , Judith-greciet , Emmanuel-huynh